Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.55 |
| ▸ | FDPS | P14324 | 5/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.47 |
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26273842 | 1.00 | SMPD1 (0.55) | SMPD1FDPSPLA2G2AS1PR2S1PR1 | |
| SCHEMBL22503349 | 1.00 | SMPD1 (0.55) | SMPD1FDPSPLA2G2AS1PR2S1PR1 | |
| SCHEMBL7167071 | 0.90 | SMPD1 (0.60) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL9484993 | 0.90 | SMPD1 (0.60) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL10380826 | 0.90 | SMPD1 (0.60) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL10379958 | 0.90 | SMPD1 (0.60) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL9484971 | 0.90 | SMPD1 (0.60) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL31579020 | 0.88 | SMPD1 (0.57) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL7603727 | 0.86 | SMPD1 (0.55) | SMPD1FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL17189670 | 0.84 | SMPD1 (0.53) | SMPD1FDPSPLA2G2AS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | HONGENE BIOTECH CORPORATION | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | FUT6, B3GNT2, GALNT6 | SMPD1 1304/4885FDPS 2756/4885PLA2G2A 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.